Gary Berman

1.2k total citations
35 papers, 586 citations indexed

About

Gary Berman is a scholar working on Immunology and Allergy, Psychiatry and Mental health and Physiology. According to data from OpenAlex, Gary Berman has authored 35 papers receiving a total of 586 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology and Allergy, 14 papers in Psychiatry and Mental health and 10 papers in Physiology. Recurrent topics in Gary Berman's work include Migraine and Headache Studies (14 papers), Allergic Rhinitis and Sensitization (14 papers) and Asthma and respiratory diseases (8 papers). Gary Berman is often cited by papers focused on Migraine and Headache Studies (14 papers), Allergic Rhinitis and Sensitization (14 papers) and Asthma and respiratory diseases (8 papers). Gary Berman collaborates with scholars based in United States, Canada and United Kingdom. Gary Berman's co-authors include Jennifer Maloney, Hendrik Nolte, Amarjot Kaur, William R. Lumry, David I. Bernstein, Jacques Hébert, Sandra M. Gawchik, Robert Croop, Martha V. White and Alexandra Thiry and has published in prestigious journals such as Neurology, Clinical Infectious Diseases and Journal of Allergy and Clinical Immunology.

In The Last Decade

Gary Berman

32 papers receiving 559 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary Berman United States 13 328 309 161 143 115 35 586
L Businco Italy 12 143 0.4× 140 0.5× 17 0.1× 62 0.4× 9 0.1× 38 305
Ashkan Heshmatzade Behzadi Iran 11 40 0.1× 33 0.1× 46 0.3× 116 0.8× 80 0.7× 20 336
M. Chastaing France 10 166 0.5× 180 0.6× 39 0.2× 325 2.3× 30 0.3× 21 501
Christina D. Schwindt United States 10 253 0.8× 85 0.3× 33 0.2× 33 0.2× 10 0.1× 21 457
Esther Röder Netherlands 11 406 1.2× 449 1.5× 24 0.1× 209 1.5× 8 0.1× 26 609
Maria Böhme Sweden 8 204 0.6× 294 1.0× 20 0.1× 267 1.9× 12 0.1× 9 472
Şemsettin Okuyucu Türkiye 10 76 0.2× 23 0.1× 11 0.1× 12 0.1× 12 0.1× 34 320
Seo Yi Chng Singapore 10 176 0.5× 46 0.1× 16 0.1× 14 0.1× 7 0.1× 15 348
А. N. Lvov Russia 8 42 0.1× 60 0.2× 39 0.2× 225 1.6× 29 0.3× 46 365
Ceren Günel Türkiye 11 50 0.2× 22 0.1× 9 0.1× 13 0.1× 9 0.1× 38 288

Countries citing papers authored by Gary Berman

Since Specialization
Citations

This map shows the geographic impact of Gary Berman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Berman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Berman more than expected).

Fields of papers citing papers by Gary Berman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Berman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Berman. The network helps show where Gary Berman may publish in the future.

Co-authorship network of co-authors of Gary Berman

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Berman. A scholar is included among the top collaborators of Gary Berman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Berman. Gary Berman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Japuntich, Sandra J., Sarah Cameron, Brittany L. Balletto, et al.. (2025). Lung cancer screening experiences among patients with a smoking history and primary care providers: a qualitative study. BMC Cancer. 25(1). 1305–1305.
2.
Chalkias, Spyros, Adebayo Akinsola, Gary Berman, et al.. (2025). Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine. The Journal of Infectious Diseases. 231(4). e754–e763. 7 indexed citations
3.
Croop, Robert, Gary Berman, David Kudrow, et al.. (2024). A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 44(4). 2225278000–2225278000. 22 indexed citations
4.
Corren, Jonathan, Stanley J. Szefler, Ellen Sher, et al.. (2024). Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. The Journal of Allergy and Clinical Immunology In Practice. 12(5). 1215–1224.e3. 18 indexed citations
5.
Berman, Gary, Alexandra Thiry, & Robert Croop. (2024). Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States. Journal of Pain Research. Volume 17. 1805–1814. 3 indexed citations
6.
Figueroa, Amparo L., Gary Berman, Haiyu Zhou, et al.. (2024). Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial. EClinicalMedicine. 74. 102720–102720. 5 indexed citations
7.
Figueroa, Amparo L., Gary Berman, Haiyu Zhou, et al.. (2023). 367. Safety and Immunogenicity of a 50-μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in Adolescents. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations
8.
Kudrow, David, Kathleen Mullin, Gary Berman, et al.. (2021). Long-term Use of Rimegepant 75 mg for the Acute Treatment of Migraine Reduces Use of Analgesics and Antiemetics (5072). Neurology. 96(15_supplement). 2 indexed citations
9.
10.
Croop, Robert, Gary Berman, David Kudrow, et al.. (2020). Long-Term Safety of Rimegepant 75 mg for the Acute Treatment of Migraine (Study 201) (4829). Neurology. 94(15_supplement). 10 indexed citations
11.
12.
13.
Maloney, Jennifer, Gary Berman, Rémi Gagnon, et al.. (2016). Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated. The Journal of Allergy and Clinical Immunology In Practice. 4(2). 301–309.e2. 38 indexed citations
14.
Maloney, Jennifer, Bruce M. Prenner, David I. Bernstein, et al.. (2015). Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Annals of Allergy Asthma & Immunology. 116(1). 59–65. 39 indexed citations
15.
Nolte, Hendrik, Niran J. Amar, David I. Bernstein, et al.. (2014). Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Annals of Allergy Asthma & Immunology. 113(1). 93–100.e3. 41 indexed citations
16.
Nolte, Hendrik, Jacques Hébert, Gary Berman, et al.. (2013). Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Annals of Allergy Asthma & Immunology. 110(6). 450–456.e4. 84 indexed citations
17.
Cady, Roger, David W. Dodick, Howard L. Levine, et al.. (2005). Sinus Headache: A Neurology, Otolaryngology, Allergy, and Primary Care Consensus on Diagnosis and Treatment. Mayo Clinic Proceedings. 80(7). 908–916. 62 indexed citations
18.
Meltzer, Eli O., Gary Berman, Jonathan Corren, et al.. (2004). Addition of ibuprofen to pseudoephedrine and chlorpheniramine in the treatment of seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 93(5). 452–459. 5 indexed citations
19.
Berman, Gary, Thomas E. Kottke, & David J. Ballard. (1990). Effectiveness Research and Assessment of Clinical Outcome: A Review of Federal Government and Medical Community Involvement. Mayo Clinic Proceedings. 65(5). 657–663. 18 indexed citations
20.
Berman, Gary, et al.. (1988). Atrophoderma (Pasini‐Pierini). International Journal of Dermatology. 27(7). 487–490. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L Businco Breakdown of academic impact, for papers by Ashkan Heshmatzade Behzadi Breakdown of academic impact, for papers by M. Chastaing Breakdown of academic impact, for papers by Christina D. Schwindt Breakdown of academic impact, for papers by Esther Röder Breakdown of academic impact, for papers by Maria Böhme Breakdown of academic impact, for papers by Şemsettin Okuyucu Breakdown of academic impact, for papers by Seo Yi Chng Breakdown of academic impact, for papers by А. N. Lvov Breakdown of academic impact, for papers by Ceren Günel
Rankless by CCL
2026